Two early-phase studies reported in JAMA1,2 address the same general question: what is the effect of bone marrow–derived cell therapy on safety and surrogate end points in patients after myocardial infarction (MI)? Other than this thematic similarity, the Timing In Myocardial infarction Evaluation (TIME) trial and the POSEIDON trial have little in common. The TIME trial1 examined 120 patients with a recent (3-7 days) acute MI (AMI) and autologous mononuclear cells (MNCs) delivered via the intracoronary route with the intervention on day 3 (n = 67) or on day 7 (n = 53). This was a placebo-controlled, multicenter trial with a fixed dose of MNCs. The major motivation was to test the concept that timing of MNC therapy within the first week after MI influences outcome. The POSEIDON trial2 involved patients with ischemic cardiomyopathy after distant MIs (years earlier) and used autologous or allogeneic mesenchymal cells (MSCs) administered transendocardially via injection catheters. Two centers recruited 30 patients and randomly assigned them into 1 of 6 permutations of cell origin (self or donor) and dosage (n = 5 patients each), with no controls. The goal of the trial was to compare the safety and efficacy of self-derived MSCs with donor MSCs in chronic ischemic cardiomyopathy.
Register and get free email Table of Contents alerts, saved searches, PowerPoint downloads, CME quizzes, and more
Subscribe for full-text access to content from 1998 forward and a host of useful features
Activate your current subscription (AMA members and current subscribers)
Purchase Online Access to this article for 24 hours
Some tools below are only available to our subscribers or users with an online account.
Download citation file:
Web of Science® Times Cited: 12
Customize your page view by dragging & repositioning the boxes below.
More Listings atJAMACareerCenter.com >
and access these and other features:
Enter your username and email address. We'll send you a link to reset your password.
Enter your username and email address. We'll send instructions on how to reset your password to the email address we have on record.
Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.